Skip to main content
Figure 8 | BMC Veterinary Research

Figure 8

From: The class I PI3K/Akt pathway is critical for cancer cell survival in dogs and offers an opportunity for therapeutic intervention

Figure 8

Effects of the combination of the class I PI3K/Akt/mTOR pathway inhibitors and Doxorubicin on cell viability. SB (A) and REM (B) cells were treated with the indicated does of the class I PI3K/Akt/mTOR pathway inhibitors, Doxorubicin, the combination of the former two drugs or vehicle control for 3 days (2 days for KP372-1). Additive, synergistic or antagonistic inhibitory effects of the drug combination on cell viability were determined when the experiment values (cell viability percentages) of the drug combination were overlapped with, lower than, or higher than Bliss theoretical values respectively.

Back to article page

BMC Veterinary Research

ISSN: 1746-6148

Contact us